

Rakuten Aspyrian changes name to Rakuten Medical

01 March 2019 | News

This name more closely reflects the company's corporate purpose of creating a global biotechnology company integrating research and development with commercial operations.



Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, announced that it has changed its name to Rakuten Medical, Inc. This name more closely reflects the company's corporate purpose of creating a global biotechnology company integrating research and development with commercial operations in order to develop therapeutics that improve cancer patient outcomes.

"We are aiming to deliver PIT platform to as many cancer patients and as early as possible worldwide. Our new name that becomes effective today, Rakuten Medical, better aligns with our goal of developing a global brand that resonates within the pharmaceutical and medical device industries," said Mickey Mikitani, chairman and CEO of Rakuten Medical. "Despite our name change, our mission of 'Conquering cancer, For life' will not change. We are stronger today than ever before as we continue building the organization necessary to conquer cancer by developing innovative cancer treatments."